The stock of Avidity Biosciences Inc (RNA) has gone down by -4.01% for the week, with a -18.78% drop in the past month and a -34.59% drop in the past quarter. The volatility ratio for the week is 5.93%, and the volatility levels for the past 30 days are 5.84% for RNA. The simple moving average for the past 20 days is -4.65% for RNA’s stock, with a -20.37% simple moving average for the past 200 days.
Is It Worth Investing in Avidity Biosciences Inc (NASDAQ: RNA) Right Now?
Company’s 36-month beta value is 0.99.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNA is 108.55M, and currently, short sellers hold a 14.26% ratio of that floaft. The average trading volume of RNA on January 10, 2025 was 1.11M shares.
RNA) stock’s latest price update
Avidity Biosciences Inc (NASDAQ: RNA) has experienced a decline in its stock price by 0.00 compared to its previous closing price of 29.93. However, the company has seen a fall of -4.01% in its stock price over the last five trading days. prnewswire.com reported 2025-01-08 that SAN DIEGO, Jan. 8, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 6, 2025, the Human Capital Management Committee of Avidity’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 80,000 shares of its common stock and 40,000 restricted stock units (“RSUs”) to Charles Calderaro III, under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”), in connection with Mr. Calderaro’s hiring and appointment as Avidity’s Chief Technical Officer.
Analysts’ Opinion of RNA
Many brokerage firms have already submitted their reports for RNA stocks, with H.C. Wainwright repeating the rating for RNA by listing it as a “Buy.” The predicted price for RNA in the upcoming period, according to H.C. Wainwright is $72 based on the research report published on December 20, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see RNA reach a price target of $67. The rating they have provided for RNA stocks is “Outperform” according to the report published on November 26th, 2024.
Goldman gave a rating of “Buy” to RNA, setting the target price at $59 in the report published on September 24th of the previous year.
RNA Trading at -22.25% from the 50-Day Moving Average
After a stumble in the market that brought RNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.55% of loss for the given period.
Volatility was left at 5.84%, however, over the last 30 days, the volatility rate increased by 5.93%, as shares sank -16.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.38% lower at present.
During the last 5 trading sessions, RNA fell by -3.78%, which changed the moving average for the period of 200-days by +29.37% in comparison to the 20-day moving average, which settled at $31.39. In addition, Avidity Biosciences Inc saw 2.92% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNA starting from Flanagan W. Michael, who sale 12,742 shares at the price of $32.66 back on Dec 18 ’24. After this action, Flanagan W. Michael now owns 72,647 shares of Avidity Biosciences Inc, valued at $416,154 using the latest closing price.
MacLean Michael F, the Chief Financial Officer of Avidity Biosciences Inc, sale 11,151 shares at $32.66 during a trade that took place back on Dec 18 ’24, which means that MacLean Michael F is holding 82,942 shares at $364,192 based on the most recent closing price.
Stock Fundamentals for RNA
Current profitability levels for the company are sitting at:
- -32.09 for the present operating margin
- 0.81 for the gross margin
The net margin for Avidity Biosciences Inc stands at -27.72. The total capital return value is set at -0.21. Equity return is now at value -27.76, with -25.34 for asset returns.
Currently, EBITDA for the company is -233.5 million with net debt to EBITDA at 1.12. When we switch over and look at the enterprise to sales, we see a ratio of 314.88. The receivables turnover for the company is 0.53for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.76.
Conclusion
In a nutshell, Avidity Biosciences Inc (RNA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
